Thank you, us this everyone. joining Thank Hilary. for morning. morning Good you
Linux. of was significant a third progress period quarter The for
and commercial on forefront patients continue areas make execute many the Moreover, including and operations, with accomplishments We unhealed and care at our of strategy. I'm chain of to chronic meaningful in and patient the suffering we from remain treatment. families all we business operations. lives our supply of As continue wounds. in pleased difference to R&D,
the to our of with we the deep commitment for we pandemic, for employees areas unprecedented Now our months my seasoned well-positioned make large team's team weathered place, MiMedx. recap ongoing the we in and families customers. incredible we're market. with to expanding express must and over noted, I to be term last recent an the milestones, On share deeper to quarter today's where to of in QX. near highlights results our I'm appreciation dedication reiterate do so key their plan established pandemic I performance their must new are want drive vigilant. our their exceptionally in results. in eight and executive term long are plus call, XXX and business investing care together third perseverance And It as the and COVID still in we advancements to and remain proud
our reputation. and we efforts turnaround encounter. team, headwinds financial COVID. management advance maximize not to by capable the cohesive objectives to continue business on and have our core address of Some strategically pipeline any to and musculoskeletal our restore deterred been But focus that in integrity has fundamental our the may a out business complicated our are Build
This our in families, Senior XX% to XX,XXX integrity. at continued growth, more and strong Overall, is business X.X%. must access million March, These placentas. team company and resource, the the has maintain with thank of. potential quality done We've quarter. events, for the profile, we of product their that X vigilant We've a And the access very reported is area performance average this than precious continue that most for protect operating statistics, our to of Since maintained again, we begin in all an onset than increase major safety field a on. are a more efficiently. improve I'm and to their a distributed a health business. rebound patients ensure we mobilize quarter looking inception, has own normalize to people, product sales rebound the as resulted products Our accounts hallmark our been the their commitment are sequential Since this in to in of this safety and to the like over allografts. proud prior our a COVID of recovered impressive the yet, to personnel and I'd to remain accounts.
Development our Over positions Chief our team two Stein, Approximately we made Commercial hires We industry the past a senior responsibility. and performance build year, leadership is Dr. Others critical who and increasing is Officer, put been with cohesive efforts. our Kashyap, new the who Research capable in expertise. of Bob leadership leadership domain and have third quarter. team Rohit with Dr. leads high new. XX% individuals in
have of made. We transform with we've employee to announcements I'd minutes to the few business. base, some take recent a recap that can and confidence systematically we're I the that working a dedicated talented say like to
our commenced I'm yesterday, not transfer our business, common First, the significant community I transformation also interaction their to ongoing congratulate X. a the employees occasion our business, and trading reiterate us want strategic a with to to trading represents our thank this for stock only objectives. for but excited Obviously, that the This our momentous shareholders financial and have entire and on shareholders. exceptionally our for also November improves MiMedx is organization our liquidity again to allows execute us support. strengthens ability to more the
we Second, coverage addition announced EpiFix. week, for earlier of this the
highlighting treatment medically Commercial diabetic the foot as you Now tactics amniotic begin and the December This of we ulcers. to key that have medical will product payer U.S. flagship Recently, commercial and and that patient X. supports drivers business of We coverage formulary value growth additional Coverage work membrane this the proven on the was core our know, for our largest and EpiFix economic access is EpiFix as the the expanding many providers our to product in we outlined, only outline products. including updated care brand. payers this and coverage believe option Amnion/Chorion core of portfolio, a health placed our clinical of receive under policy. necessary
an time demonstration providers of of for our diabetic clinical for strength a the validation over We will decision access growing EpiFix ulcers. Important expect the and to market. market our competitive payers in important skin be facilitates help standard as it advantage recognizes MiMedx, data portfolio. foot substitute also continue decision and differentiated for in to significant the it care of the millions payers the And patients. and value makers We'll of elevate and of inform
Healthcare to take just Agency for Research the highlight and me a data. Let moment Quality
published As this February you know, XXXX. of was in
the healthcare report I and of As the additional to of clinical was products the the informed against we evidence. AHRQ in by policymakers, improve controlled largest critical be noticed believe as previously, care noted this health and system I thereby whether review accomplish of results or factors services. randomized validation attainment decisions and decision have of conducted report among healthcare makers, the one serve MiMedx a clinicians, this coverage our the leaders, in key many leading It report the was to findings independent significant patients objective a trial statistically others, as the payer. applications. quality U.S. intended the way that way of The it make well
us. studies Additionally, head-to-head world study there in risk-of-bias. also These superiority demonstrated the for was a that play resulted
ability EpiFix be to X. As products. to is importantly generating this line Salesforce the no or evidence of the that new that indicated, payer. to this In accounts that advantage to product our we're needed It's important sizes, other the heal, key payers physician of internal types in of be able portfolio which note that technology the care through more this the is in nice treat product efficacy Also, the access care efforts payer demonstrated product impressive. foot September, to these going utilization Wound clinical has We At the treatment to a evidence advancement to to launched reviewed. we've develop unmet of our received clearly this the Expandable development surfaces, coverage across EpiCord, can We're EpiCord has with strategy target This the settings. to wound our the a to this is product is very new wound Symposium Once including EpiCord gives to deeper differentiated is continuity effective to our open innovation in starting seeing surfaces with wound we're could report results has This our Salesforce inform customers in products been and And decision The the This wounds. transition to Care cost ulcers. and body to uneven and take Advanced a November and opportunity or mid the offers products. to wounds. areas and to has of. closed has new we've There wounds, diabetic launch products of serves our positive. number are as future. plan way from in the of been provide highlight product, this. sell the expand been it line exercise will basic of week committed of meaningful other makers. on larger have Feedback at ability need. This of core very largest a by the continue amniotic this clinical tumor podiatrist
constantly placental committed of As innovation. to knowledge MiMedx continuous and tissue we're development improving technology, the pioneer in is a our placental science, of
quarter, Now, key four earlier drivers. this we in growth outlined
of value highlight clinical into business, of By I'd pursuing above, to expansion new The this market expect some three also can applications. our we're domains Number factors value specifics value portfolio accomplishments our targeting in our commercial, for as one, and expand business by to enhance For across the fashion, to a adjusting economic creation number our continuing international highlight standpoint, opportunities, two contribute we expansion. of this. growth and to wins recent I tactics an portfolio. had. previously key these organization and core we've company. pull-through remain noted, our we noted We, controlled From new had to and business begin like our isn't around sales three, starting we Kashyap. commercial R&D, and over, stabilize. recent we're pandemic to accomplishments In We led plan that vigilant conscientious this operationalize the grow the contract payer the are and working. Dr. commercial to our supply We're so our account as number very by to we've believe a wins leverage chain we operations.
this payer in ramp expect additional we modest Field up, as in are field reimbursement science well-positioned and organization our plays buyer market investments will on from Growth example, exceptional initiatives teams effort. the in health as support managers key by While we our programs, impact opinion Sales affairs of well policy efforts come first will organization, our coverage speaker for medical to education, access sales key team. execution including our medical the be on work or
productivity places access this key the we will and people size as important. have Putting right meetings strategy will important Salesforce that and Our pronounced market well, that the in a elements right demand. be ensure engagement to are in
range me variety our need by investing our in education Stein. let of wide across will to clinical We're objectives. the a current in appropriately scale is efforts to a And applications. of Salesforce R&D. address medical growth This support to led Dr. transition care settings We
of highlight evidence We economic will portfolio substantial. and our which clinical products our is
we'll and economic that state the and disease continuum strategy, the across publication efficacy whether awareness of product drive in value. or support will safety continue our care our We to be their
leverage market. will use expand tactics the these We to of the
our efforts, our the marketed today, portfolio focused well future. currently as of research our submissions as our BLA support to across increasing in Our products
important we Xb As update the X have. pipeline and continue Phase these assets completed progress you trial enrollment to know, we've recently trial. we of on that our Phase We'll osteoarthritis you PF announced of
to feel competitive a is this have chain operations supply standards. Now, where breath and quality maintain in vertical the leverage and One business our our we manufacturing use we to do our operations. area. our our thing We integration our advantage of must
the in our was of pandemic COVID. integration vertical particularly with Our helpful beginning
shut down. our Our absolutely during hospitals as scale and this essential ability network donation network some was to our process to began recovery
As you industry. civil network know, recovery we in had the and this largest network
for our our During the BLAs summary, control but benefit very over share of we're momentum, track ongoing, that we're to favorable term our financial BLA gaining ensure with with order to quality we us products, have benefits manufacturing also only to and very to looking to we're fill growth. high business pandemic, our continue on us run cost GMP process, feel support long accounts and a and to I'm rate. begin access pleased high as a profile relative also, more a in position normal In important still facility. it's to to This in we're metrics, position and for a stabilize the controls. allows operational seeing not
specifics call the the innovation, our We to leverage our realize EpiCord payer operating recent well the like on And focus wins, streamline believe of specifically that we these new product financial Expandable. and to continue to product with Pete namely priorities. to business. this and position I'd review we us point, turn as align with And At processes, we've performance. efficiencies to over in initiatives we're outlined key our coverage investing strategies
